Grifols Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Grifols key operating metrics including Bioscience R&D Projects (Clinical Phase), environmental, and social and governance score (ESG).

Bioscience R&D Projects (Clinical Phase)

FY, 2020

Bioscience R&D Projects (Discovery Phase)

FY, 2020

Countries

110

H2, 2021

Operating Metrics

Metrics	FY, 2017	FY, 2018	FY, 2019	FY, 2020	FY, 2021
Bioscience R&D Projects (Clinical Phase)	26	28	21	21
Bioscience R&D Projects (Discovery Phase)	14	12	15	15
Countries	100	100	100	100
Hospital Division Product Licenses	187	186	188	170
Hemoderivative Product Licenses	683	694	949	973
Plasma Obtained, liters	9.3M	12M	13.5M	15.2M	20M
Patents and Patent Applications	2.7K	3K	3.2K	3K
Diagnostic Product Licenses	2.3K	2.5K	3K	3K
Bioscience R&D Projects (Other)	18	16	19	19
Bioscience R&D Projects (Post Commercialization Studies Phase)	10	9	10	11
Bioscience R&D Projects (Preclinical Phase)	12	12	19	25
Trademarks and Trademark Applications	3.1K	3.2K	3.4K	3.5K
Plasma Collection Centers (US)	190	197
Plasma Collection Centers	190	256	295	312	366
Plasma Collection Centers (Europe)		59
Plasma Operating Center (Europe)					57
Plasma Operating Center (US)					307
Business Areas					4
Acquisitions					520
Patents and Trademarks Under Management					7.1K

50-59 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Source:CSRHub